Introduction: Abacavir and Lamivudine both are nucleoside analogs acting as reverse transcriptase inhibitors (nRTI), widely used for the treatment of HIV infection. Both the drugs are in the World Health Organization's List of Essential Medicines, which contains the most important medications needed for a basic health system.
INTRODUCTION
Abacavir and lamivudine as a combined formulation is widely used for the treatment of HIV infection. Both the drugs are nucleoside reverse transcriptase inhibitors (NRTI).
Abacavir (CAS No. 136470-78-5) is a nucleoside analog (guanosine) reverse transcriptase inhibitor (NRTI) used to treat HIV infection. Abacavir is given orally and has a high bioavailability (83%). It is metabolized primarily by the hepatic enzyme alcohol dehydrogenase or glucuronyl transferase. It is capable of crossing the blood-brain barrier.
*Address correspondence to this author at the Bioequivalence Study Centre, Dept of Pharm Tech, Jadavpur University, Kol-32, India; Tel: (+91) 033-2414 6967; Fax: (+91) 033-24146186; E-mail: tkpal@pharma.jdvu.ac.in Lamivudine is a potent nucleoside analog (cytidine) reverse transcriptase inhibitor (NRTI). Lamivudine (CAS No. 134678-17-4) has been used more widely for the treatment of chronic hepatitis B at a lower dose than for the treatment of HIV. Both the drugs are on the World Health Organization's List of Essential Medicines, a list which contains most important medication needed in a basic health system [1] .
Abacavir sulfate/lamivudine (ABC/3TC) is widely used as a nucleoside reverse nucleoside transcriptase inhibitor combination drug for initial HIV-1 treatment. Numerous trials have been performed so far to study the antiretroviral efficacy, safety and tolerance of this fixed dose combination. In one of those trials, combination therapy containing abacavir-zidovudinelamivudine had shown a highly effective antiretroviral regimen, resulting in substantial reductions in plasma HIV-1 RNA level which may be compared to the other combined protease inhibitor drugs [2] . In another randomized, blind bioequivalence study involving 1858 eligible patients, comparison had been done between four once-daily antiretroviral regimens as initial therapy for HIV-1 infection: abacavir-lamivudine or tenofovir disoproxil fumarate (DF)-emtricitabine plus efavirenz or ritonavir-boosted atazanavir. As a result of which, the time required to virologic failure and the occurance of first adverse event were found to be significantly shorter in patients randomly assigned to abacavirlamivudine than in those assigned to another regimens [3] .
According to the literature survey no bioanalytical method were found to quantify abacavir and lamivudine simultaneously in human plasma or any other biological matrix till date. LC-MS/MS methods were found to be used for quantification of lamivudine and abacavir in human plasma either individually or in combination with other antiretroviral drugs [4] [5] [6] .
In the present investigation, a randomized, two period, two treatment crossover study of two preparations of FDC tablets containing abacavir 600mg and lamivudine 300mg of Lok-Beta Pharmaceuticals Pvt. Ltd. Mumbai and Abamune-L 600/300mg Tablet (containing abacavir 600mg and lamivudine 300mg) of Cipla Laboratories Ltd, India had carried out in 24+2 healthy male, adult, human volunteers under fasting condition to establish the bioequivalence of the two formulations.
EXPERIMENTAL

Drug (Test and Reference) Information
Reference Preparation (A)
Abamune-L 600/300mg tablet (containing abacavir 600mg and lamivudine 300mg); 
Chemicals and Reagents
Acetonitrile (ACN), Ethyl acetate, Ammonium formate were purchased from Merck (MERCK India Ltd., Mumbai). All solvents used during the analysis were of HPLC grade. Other chemicals and reagents of analytical grade were used throughout the study. HPLC grade water with a resistivity of 18 MΩ was obtained from a Milli-Q gradient system of Millipore (Elix, Milli-Q A10, USA).
Study Design
Present study was a single dose, random, two treatment and crossover study, with a washout period of 7 days between the two dosing sessions. In each dosing session, volunteers received either of the Test or the Reference preparation containing Abacavir 600mg and Lamivudine 300mg only on the day of study at a fixed time according to the approved protocol. The study was in accordance with the guidelines standardized by Central Drug Standard Control Organization (CDSCO), New Delhi, India set for BA/BE Studies [7] .
Informed Consent
Before recruitment and enrollment into the study, each prospective candidate was given a full explanation of the study. Once this essential information was provided to the subject and once the physician in charge had the conviction that he had understood the implications of participating in the study, the subject was asked to sign the informed consent form.
Ethical Clearance
Guidelines as drawn up by the Institutional Review Board were followed regarding the treatment of human volunteers in the study. These guidelines met the requirements of the U. S. Code of Federal Regulations (Title 21, Part 56) [8] , the Declarations of Helsinki and the Canadian MRC Guidelines. The protocol and the informed consent form were submitted to the Ethical Committee prior to the initiation of the study. The approval of the Ethical Committee was taken in advance of the study commencement. This study protocol was also approved by the Drugs Controller General of India (DCGI), New Delhi, India and as well as by the HURIP Independent ethics Committee, Kolkata, India [9, 10] .
Subject Selection
Healthy adult men Indian human volunteers within 18 to 40 years of age were ( Table 2 ) selected from the panel of volunteers recruited by CPU. The selected volunteers were screened before the commencement of the study and enrolled as per the study specific inclusion/ exclusion criteria.
Randomization and Dosing of the Volunteers
The volunteers were randomly sorted on the previous day of study initiation of study. During the study phase I and II, each volunteer received either the test or reference preparation as a single dose, only on the study day, at a fixed time as per the Table 2 with 240ml. of water after overnight fasting of at least 10hrs. 
Sampling Schedule and Collection
Instrumental Conditions
Mass spectrometric detection was performed by API 2000 triple quadrupole mass spectrometer (Applied Biosystems/MDS SCIEX, Toronto, ON, Canada) equipped with an Turbo electrospray ionization (ESI) interface. The tandem mass spectrometry parameters for the detection of abacavir, lamivudine and the internal standard (IS, nevirapine) were optimized by carrying out full scans in positive ion detection mode using ESI as an ion source. The detection and quantification of the analytes and IS were performed in multiple reaction monitoring (MRM) mode. Quadrupoles Q1 and Q3 were set to unit resolution. Full Q 3 scan positive ions Turbo Ionspray of analytes are presented in Figure 1 (A and B) . Data acquisition and quantitation were carried out using Analyst software version 1.5 (Applied Biosystems/MD SCIEX). The mass spectrometry conditions optimized for lamivudine, abacavir and IS are summarized at Table 1.
Liquid Chromatographic Method
Chromatographic analysis was performed using a Shimadzu HPLC system equipped with LC-20AD Binary pump, SIL-20A Autosampler, CTO-10ASvp Oven and CBM-20A Lite System Control Compartment. Separation was carried out using an Agilent ZORBAX C18; 50x4.6mm column, having particle size-5µm. The mobile phase consisted of ACN: 10 mM Ammonium Formate in water :: 9 : 1 (v/v) at a flow rate of 0.5 mL/min. The auto-sampler was maintained at 4•C. The total run time for each sample analysis was 3.0 min.
Bio-analytical Method Development and Validation
In a stoppered test tube, 100 µL of plasma was taken. To this 10 µL of Internal Standard (IS; nevirapine 2000 ng ml Following these steps, calibration samples were prepared by spiking the serial dilutions of the analytes in blank human plasma along with a double blank and blank sample. The concentration range for lamivudine and abacavir were (10-10000) ng mL -1 for both. The calibration curve for each analyte was drawn by plotting the ratios of areas of the analyte and IS against the ratios of the respective concentration of the analyte and IS.
The method was fully validated for accuracy, precision, sensitivity, recovery, linearity, and stability in accordance with the updated version of FDA guidelines [8] , using nevirapine as IS. Linearity, precision, and accuracy were tested by analysis of five batches of spiked plasma quality-control (QC) samples. Each batch of spiked plasma samples included one complete set of calibration standards (comprising six different concentrations, blank and blank with internal standard) and QC samples at low (30 ng mL ; HQC) concentrations.
Pharmacokinetic Parameters
The plasma concentration levels achieved by the administration of the studied drugs in each volunteer and collected for the measured content of the dosage form used to establish the pharmacokinetic profile of 
Statistical Analysis
Usual descriptive analysis including the mean and standard deviation (SD) were used for the variables such as the height, weight and age. These statistical parameters including coefficient of variance are also used to describe plasma concentrations at each individual time point as well as the pharmacokinetic parameters. Following statistical tests were applied on untransformed (t max , C max , AUC (o-t) , AUC (o-α) ) and logtransformed pharmacokinetic data (C max, AUC (0-t), AUC (0-α) ). Anova of t max , C max , AUC (o-t) , AUC (o-α) were subjected to a 3-way ANOVA accounting for subjects, period and treatment. 90% confidence interval (CI) consistent with two-one sided t-test with the significance level of 5% for untransformed and log transformed parameters (t max , C max, , AUC (o-t) , AUC (o-α) ). Products will be considered as bioequivalent if the 90% confidence interval (CI) of difference in the average values of logarithmic AUC and Cmax between test and reference preparations is within the acceptable range of Log (0.8) to Log (1.25).
RESULTS AND DISCUSSION
Demographic Data and Randomization of Volunteers
The average age and BMI of the male subject were found to be 28.42 years and 21.36 kg/m 2 respectively. Table 2 shows the details of the age, height, weight and BMI data of each volunteer. As it is a crossover two phase study, each volunteer was exposed to the reference and test drugs either in phase-I or phase-II.
Liquid Chromatographic Method Development and Validation
A simple, reproducible, sensitive, and specific LC-MS/MS method was developed and validated for the simultaneous determination of abacavir and lamivudine in human plasma.
For lamivudine, Within-run and between-run precision values (%CV) were ranged from 2.15% to 4.79%. Within-run and between-run accuracy values (%nominal) were 99.20-102.20% for LQC, 102% for MQC, and 100.90-101.60% for HQC samples. The stability of LQC, MQC, and HQC samples were determined after three freeze thaw cycles comparing against freshly thawed samples of the same concentration. The stability of lamivudine ranged between 94.57-99.90% after three cycles. For abacavir, Within-run and between-run precision values (%CV) were ranged from 5.062% to 9.570%. Within-run and between-run accuracy values (%nominal) were 97.20-102.30% for LQC, 101.75-102.39% for MQC, and 101.74-102.95% for HQC samples. Recovery after extraction was calculated to be 99.13-102.45% by comparing the peak areas of the plasma LQC, MQC, and HQC samples to the absolute peak area of the unextracted standards containing the same concentrations of abacavir. The stability of LQC, MQC, and HQC samples were determined after three freeze thaw cycles comparing against freshly thawed samples of the same concentration. The stability of abacavir had been found to be ranged between 96.65-99.85% after three cycles. Chromatograms for Blank + IS, LLOQ are represented as Figure 2 and Figure 3 respectively.
Plasma Sample Analysis
Volunteer plasma samples were analysed by LCMS/MS after extracting the drug from plasma and injecting it on the Agilent ZORBAX C18 column for chromatographic analysis. Abacavir and lamivudine were detected in the plasma from 0.5 hour to about 24.0 hours for both test and reference preparations. The time of peak plasma levels of abacavir in test and reference preparation were achieved between 1.0 to 2.0 hours and in case of lamivudine it was found to be between 1.0 to 3.0 hours. The mean peak plasma levels of abacavir and lamivudine with reference preparation, ABAMUNE-L (containing abacavir 600mg and lamivudine 300mg) ranged between 5860 -6450 ng/ml and 3920 -4650 ng/ml respectively, while for the test preparation of FDC tablet containing abacavir (600mg) and lamivudine (300mg), it ranged between 5820 -6470 ng/ml and 3880 -4510 ng /ml for abacavir and lamivudine respectively. Chromatogram of extracted volunteer plasma taken at 1hr. after oral admintration of the drug is represented as Figure 4 . Mean plasma concentration-time curves for Abacavir and Lamivudine (n=24) following single-dose administration of test and reference (both FDC tablet Containing Abacavir 600mg and Lamivudine 300mg) tablets are represented as Figure 5A and Figure 5B respectively. 
CONCLUSION
In the present study attempts were made to develop a rapid, sensitive LC-MS/MS bioanalytical method for simultaneous determination of abacavir and lamivudine in human plasma. The developed method has been found to be at par to the standard industry guidelines for validation.
On the basis of comparison of the AUC 0-t for abacavir and lamivudine after single dose administration, the relative bioavailability of the test and reference preparation were found to be 104.00% and 101.65% respectively. No occurrence of adverse event was reported by the volunteers throughout the study duration. Therefore it may be concluded that the test preparation was found to be bioequivalent with the reference preparation.
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